Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 4Myelodysplastic Syndromes 3Triple Negative Breast Neoplasms 2Rectal Neoplasms 2Prostatic Neoplasms 2Lymphoma 2Leukemia 2Hematologic Neoplasms 2Colonic Neoplasms 2Cardiovascular Diseases 2Cardiotoxicity 2Carcinoma in Situ 2Breast Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Peritoneal Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Nose Neoplasms 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1

Interventions

Injections 2Infusions, Intravenous 2tislelizumab 1sacituzumab govitecan 1bintrafusp alfa protein, human 1Tomography, X-Ray Computed 1Platinum 1Nivolumab 1Ipilimumab 1Iodine-125 1Electrocardiography 1Echocardiography 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Solid Tumors × Electrocardiography × 1 year × Clear all
NCT03388632 2025-12-18

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
31 enrolled 20 charts
Other solid neoplasm

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡